TherapeuticsMD, Inc.
TXMD
$1.46
-$0.06-3.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.65% | 142.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.65% | 142.24% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -17.65% | 142.24% | |||
| SG&A Expenses | -16.26% | 8.70% | |||
| Depreciation & Amortization | 0.00% | 1.05% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.03% | 8.08% | |||
| Operating Income | 7.21% | 59.26% | |||
| Income Before Tax | -90.83% | 181.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -90.83% | 185.69% | |||
| Earnings from Discontinued Operations | 1,600.00% | 135.29% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -72.41% | 184.38% | |||
| EBIT | 7.21% | 59.26% | |||
| EBITDA | 10.31% | 67.59% | |||
| EPS Basic | -72.48% | 184.25% | |||
| Normalized Basic EPS | -85.03% | 193.63% | |||
| EPS Diluted | -78.99% | 177.40% | |||
| Normalized Diluted EPS | -85.03% | 193.63% | |||
| Average Basic Shares Outstanding | 0.00% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||